Introduction
Hematopoietic stem cells (HSCs) are rare cell populations that are capable of self-renewal and blood cell production [1] . Therefore, they maintain hematopoiesis throughout life. Further, HSCs might be able to differentiate into cells of other tissues such as muscle cells [2] . Cells that express CD45 and CD34 but lack CD38
and lineage antigens (CD45 + CD34 + CD38 -Lin -) are a well-documented HSC population [3, 4] . Recent data from multiple groups have indicated that cells which express CD45 but lack expression of CD34, CD38, and lineage antigens (CD45 + CD34 -CD38 -Lin -) are probably less mature HSCs than are CD45 + CD34 + CD38 -Lin 620 CD45 -Clonal Cells in MDS face marker that is expressed on all hematopoietic cells, from HSCs to mature blood cells, except for erythroid cells, platelets, and plasma cells, which lose this antigen during maturation [7] . Myelodysplastic syndromes (MDS) are hematological neoplasms in which neoplastic myeloid cells (i.e., neutrophilic, monocytic, megakaryocytic, and erythroid cells) proliferate in the bone marrow (BM). There is a hypothesis that the MDS malignant transformation occurs at the committed myeloid progenitor cell level [8] , but recent data suggest that the transformation occurs in CD45 + CD34 + CD38 -HSCs in MDS [9] . The neoplastic hematopoietic cells in MDS have various degrees of defective differentiation capability in each patient, and thus the percentage of immature blast cells in the BM differs among patients. MDS is classified into several subgroups, based mainly on the blast percentages in the BM and peripheral blood (PB) [10] . During the clinical course, patients with MDS often show a transition from the original MDS subtype to another subtype with a higher blast percentage and, finally, to secondary acute myeloid leukemia (AML) [11] . Recently, based on the findings that immature cells are lighter than mature cells [12] , a new density-centrifugation method for enriching blastoid immature cells from PB and BM samples was developed [13, 14] . In a prior study, we used this method to prepare blast-rich MDS specimens for immunophenotyping and found that MDS blasts have the immunophenotype of committed myeloid precursors (CD45 + CD34 + CD38 + CD13 + CD33 + ) [15] . Further, we showed that, in accordance with disease progression (increase in blast percentage), the phenotype of MDS blasts became more immature (e.g., gain of CD7 and c-kit expression), at least in some patients [15, 16] .
Here we report detection of CD45 -CD34 -CD38 -Lin -blastoid cells having a chromosomal aberration in the PB and BM samples of MDS. These cells were detected in the advanced disease stages of MDS. The freshly isolated CD45 -CD34 -CD38 -Lin -cells did not form any hematopoietic colonies but differentiated into hematopoietic colony-forming cells and fully mature myeloid cells when cultured together with murine stroma cells. This newly identified cell population has the most immature immunophenotype so far identified in the hematopoietic lineage and is involved in the MDS clone.
Materials and Methods

Subjects
Patients with MDS (either of two subtypes: refractory anemia with excess blasts [RAEB] or RAEB in transformation [RAEBt]) or acute leukemia transformed from MDS (AL-MDS), diagnosed according to the French-American-British criteria [10, 17] , were the subjects of this study. Patients who had previously undergone cytotoxic chemotherapy and those with a secondary MDS were excluded. Cytogenetic analyses were performed using standard G-banding with trypsin-Giemsa staining. Karyotypes were interpreted using the International System for Cytogenetic Nomenclature criteria [18] .
Blastretriever (BR) Density Centrifugation
Heparinized BM cells, which were aspirated for clinical diagnosis, and heparinized PB were obtained from the patients. The study was approved by the Institutional Review Board of Nippon Medical School, and informed consent was obtained from all subjects. Samples were enriched for immature blastoid cells by density-gradient centrifugation using BR (Japan Immunoresearch Laboratories Co., Takasaki, Japan, http://www.jimro. com) according to the manufacturer's instructions, as reported previously [13] [14] [15] [16] . The blastoid cell-enriched samples were subjected to flow cytometry (FCM) to detect CD45 -CD34 -CD38
Lin -cells. The cell differential of these samples was determined for cytospin preparations (after Wright-Giemsa staining, 100 nucleated cells were examined for each cytospin).
FCM
Immunophenotyping was performed by three-color FCM, in which the optimal quantity of antibodies to be used was determined in preliminary experiments and each cell population was gated by a CD45 gating method, as described previously [15, 19, 20] . 
Fluorescence In Situ Hybridization (FISH)
Isolated cells were subjected to simultaneous morphological and FISH analyses as described previously [14, 23] . In brief, microscopic images of Giemsa-stained cells on cytospin glass slides were saved in a computer, and the location of the cells was recorded. Then the slides were treated with 70% ethanol for a few seconds, 75 mmol/L KCl for 10 minutes, and Carnoy's fixation solution for 5 minutes. Next, the slide was treated with trypsin digestion (0.005% trypsin in phosphate-buffered saline [PBS], pH 7.5) for 10 minutes at 20°C, washed with PBS, dehydrated with 70%, 85%, and 100% ethanol, immersed in 2× standard saline citrate solution containing 0.1% Nonidet P-40, and dehydrated through 70%, 85%, and 100% ethanol. The probe was designed to hybridize the centromere region of chromosomes X, Y, and 7, respectively (CEP X, CEP Y, and CEP 7) (Vysis, Downers Grove, IL, http://www.vysis.com). Denaturation, hybridization, and posthybridization wash were performed according to the manu- 
Cell Coculture with HESS-5 Murine Stroma Cells
The hematopoietic-supportive stromal cell line HESS-5 was previously established from murine BM [24] , and its application to hematopoietic cell cultures was reported [21, 22] . 12 .5% fetal calf serum (FCS), and various combinations of human cytokines. The final concentrations of cytokines were as follows: interleukin-3 (IL-3), 10 ng/mL; thrombopoietin (TPO), 50 ng/mL; stem cell factor (SCF), 50 ng/mL; Flk2 ligand, 50 ng/mL; vascular endothelial growth factor (VEGF), 10 ng/mL. IL-3, SCF, and TPO were provided by the Kirin Brewery Co. (Tokyo, http://www.kirin.co.jp/english). Flk2 ligand and VEGF were purchased from Immuno-Biological Laboratories. After an appropriate interval (3-7 days, depending on cell growth), half of the volume of the culture medium was harvested and replaced with fresh medium as follows. The cells in the harvested medium were collected by centrifugation, suspended in fresh medium, and returned to the culture. When cell growth had become extensive, the cell culture was scaled up. When the cultured cells were analyzed, all cells were harvested by vigorous pipetting and washed in PBS before use.
In Vitro Colony-Forming Assay and Long-Term Culture-Initiating Cell (LTC-IC) Assay
The colony-forming potential of the freshly isolated CD45 -
CD34
-CD38 -Lin -cells, CD45 -CD34 + CD38 -Lin -cells, and CD34
+ myeloblasts was examined in a methylcellulose medium (MethoCult GF H4434; Stem Cell Technologies, Vancouver, British Columbia, Canada, http://www.stemcell.com) as described previously [21, 22] . The medium was supplemented with optimal concentrations of human recombinant cytokines such as IL-3 (10 ng/mL), SCF (50 ng/mL), granulocyte-macrophage colony-stimulating factor (10 ng/mL), and erythropoietin (3 U/mL). MethoCult cultures were incubated at 37°C in a humidified atmosphere of 5% CO 2 , and colonies were scored after 14 days of culture.
To assess the LTC-IC activity, the CD45 -CD34 -CD38 -Lin -cells and CD34 + myeloblasts that had been cultured with HESS-5 cells for 5 weeks were similarly examined for their colony-forming potential.
SCID-Repopulating Cell Assay by the Intra-BM Injection (IBMI) Method
The animal experiments were approved by the Animal Care Committee of Kyoto Prefectural University of Medicine and carried out at that university. Severe combined immunodeficient (SCID)-repopulating cell assay by the IBMI method was performed as reported previously [6, 25] . Five-week-old nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice (Central Institute for Experimental Animals, Kawasaki, Japan) were handled under sterile conditions and maintained in germfree isolators located in the Central Laboratory Animal Facility. Purified cells were transplanted by IBMI into sublethally irradiated (250 cGy) 8-to 12-week-old mice. Briefly, after sterilization of the skin around the left knee joint, the knee was flexed to 90 degrees, and the proximal side of the tibia was drawn to the anterior. A 27-gauge needle was inserted into the joint surface of the tibia through the patellar tendon and then inserted into the BM cavity. Using a Hamilton microsyringe, cells suspended in 10 μL of α-medium were carefully injected via the bone hole into the BM cavity. The mice were killed 10-14 weeks after transplantation, and the BMs from the bilateral femurs, tibiae, and humeri were flushed out using α-medium containing 10% FCS. The presence of human cells was analyzed by FCM. Mice were scored as positive if more than 0.1% of the total murine BM cells were positive for human CD45. In some experiments, the mice received an intraperitoneal injection of 20 μL of anti-asialo GM1 antiserum (Wako, Osaka, Japan, http://www.wako-chem.co.jp) in 400 μL of PBS to suppress natural killer cell activity. CD45 + CD34 -Lin -cells, which were obtained from cord blood as described previously [6] , were used as a positive control.
Statistical Analyses
Differences between three or more groups of data of continuous variables were analyzed by one-way analysis of variance. Differences in categorical variables were evaluated using the chisquare test. A p value of less than .05 was considered to be statistically significant. Figure 1 shows a representative example of flow cytometric analysis of a sample after BR density centrifugation. In the CD45 versus side scatter (SSC) display, we detected a cell cluster that lacked CD45 expression and had low SSC (R3 in Fig. 1B ). The CD45 -was confirmed by using another antibody that recognizes a different epitope of the CD45 molecule. The forward scatter (FSC) showed that the size of cells in R3 ranged from lymphocyte size to myeloblast size, but cells smaller than myeloblasts were predominant (Fig. 1D) revealed that, in addition to the CD45 -, the majority of cells were negative for hematopoietic lineage antigens (CD2, CD3, CD10, CD11b, CD13, CD15, CD16, CD19, CD20, CD33, CD41a, CD56, and GPA) and stem cell-related antigens (CD34, CD38, CD117, and CD133). They were negative for HLA-DR and KDR but positive for HLA-class I antigen and CD44. Only minor subpopulations of the cells in R3 were weakly positive for CD7, CD34, CD38, and CD133. Therefore, in this case the dominant cells in R3 were CD45 -CD34 -CD38 -Lin -. Part of the flow cytometric immunophenotyping for CD45 -cells as well as myeloblasts is shown in Figure 1E (CD45 -cells, blue dots; myeloblasts [cells in R2], gray dots). The cardinal data of the antigen profiles for these two cell populations are presented in Table 1 (patient 1) and clearly differ considerably between CD45 -cells and myeloblasts. Figure 2 shows the plots for another patient, and it is seen that one third of the CD45 -cells (cells in R3, Fig. 2B ) expressed CD34 and a few expressed CD38 and myeloid antigens (blue dots in Fig. 2C) 625 were blastoid cells that had scanty cytoplasm with no granules (Fig. 3B) 
Results
Detection of CD45
CD45
-Clonal Cells in MDS were cultured under the present culture conditions, the cell number had increased 370-fold (mean of four experiments) on day 7 of the culture. In contrast, when CD34 + myeloblasts from six MDS patients were cultured, the increase in cell number was much less. In two patients (patients 2 and 3), almost all the cultured cells died during the first 7-10 days of culture. The data for the other four MDS patients are shown in Figure 4B . Among these four patients, the highest increase in cell number on day 7 was 50-fold (patient 4; the solid circles in Fig. 4B ). These inferior results in MDS were expected because we and others had documented that the expansion and differentiation abilities of HSCs and hematopoietic progenitors were often markedly reduced in MDS patients compared with normal subjects [9, [27] [28] [29] [30] . Moreover, the fold increase in the cell number of cultured CD45 -CD34 -CD38 -Lin -MDS cells was much less compared with the cultured CD34 + myeloblasts in MDS. In addition to patients 2 and 3, in one other case (patient 5, the open star in Fig. 4B ) almost all the cells in CD45 -CD34 -CD38 -Lin -cell culture died during the first 10 days of culture. For the remaining three patients, the cell number decreased during the first 7-10 days, while small clusters of cells (aggregates of two to four cells) began to appear on days 7-10 of culture. These cell clusters later produced more cells. This is in contrast to the CD34 + myeloblast culture, in which cell clusters began to appear on day 3 of culture. The fold increase in cell number was always less in the CD45 -CD34 -CD38 -Lin -cell cultures compared with CD34 + myeloblast cultures for each patient (Fig. 4B) . Time-course photographs of the cultured cells from a representative patient are shown in Figure 4C . In two patients from whom relatively large numbers of cells were obtained for culture, we examined the immunophenotypes of the cultured cells at various time points. Representative results are shown in Figure 5 . Regarding CD34 + myeloblast culture, the percentage of CD34 + cells in the culture decreased with time and became 0% on day 35 of culture ( Fig. 5A, lower panel) expressing myeloid antigens had appeared (Fig. 5A, upper panel (Fig. 5B) . The findings for WrightGiemsa-stained cytospin preparations at various time points were consistent with the FCM data and confirmed that both cultures produced myeloid cells in various stages of maturation (Fig.  5C ). FISH analyses also confirmed that these cells were clonal in origin (data not shown).
Colony-Forming Activity and LTC-IC Activity of
The results are shown in Figure 6 . It has been reported that colonyforming activity is often defective in MDS [27, 28] Demonstration of human hematopoiesis in NOD/SCID mice has been used to confirm HSC activity of human cell samples [31] . However, the published data indicate that MDS stem cells seldom or never establish hematopoiesis in NOD/SCID mice [9, 32, 33] . Therefore, in this study we used IBMI of MDS cells to NOD/ SCID mice. The IBMI technique detects HSC activity more sensitively compared with the conventional method-intravenous injection of HSCs to NOD/SCID. That is, IBMI, but not the conventional method, can detect HSC activity in CD34 -HSCs, and it needs fewer HSCs to reconstitute human hematopoiesis than does the conventional method [6] . Moreover, we treated some NOD/SCID mice with anti-asialo GM1 antiserum to facilitate HSC engraftment. Despite these approaches, we have so far been unable to detect any NOD/SCID repopulation activity in CD45 -
CD34
-CD38 -Lin -MDS cells (Table 5 ). 
Discussion
Whether HSCs are actually involved in MDS remains controversial [34] . There is a hypothesis that MDS malignant transformation occurs at the committed myeloid progenitor cell level [8] . However, it was recently reported that CD45 + CD34 + CD38 -HSCs are involved in a malignant clone of MDS [9] . -Lin -cells detected in this study arise due to loss of antigen expression during ex vivo cell processing. In particular, it is known that CD34 expression can change according to the cell activation status [39] . In this study, the treatment with BR density centrifugation alone, which is a 10-minute centrifugation method that can speedily enrich immature cells [13] [14] [15] [16] BR density centrifugation was developed based on the finding that immature blastoid cells are lighter than mature cells [12] . It is also known that hematopoietic progenitors and HSCs are lighter than most other BM cells [40] , which is probably the reason we were able to detect From the technical point of view, the most problematic point in conducting the study reported here was that the proliferating and differentiating capacities of MDS cells are much less than those -CD34 -CD38 -Lin -cells, which we newly identified here, are phenotypically the most immature among hematopoietic cells so far reported and involved in the malignant clone in MDS. Although we could not show NOD/ SCID repopulating activity in these cells, our in vitro data suggest that these cells have a role in the clonal hematopoiesis in MDS. Verification of the presence of these cells in normal condition and elucidation of their precise role(s) in normal and MDS hematopoiesis await further studies.
